Double-filtration plasmapheresis reduces type I interferon bioavailability and inducing activity in systemic lupus erythematosus

References

• Tsokos GC, Lo MS, Costa Reis P, et al. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2016;12(12):716–730. doi: 10.1038/nrrheum.2016.186.
   PubMed Web of Science ®Google Scholar
• Rönnblom L, Alm GV, Eloranta M-L. The type I interferon system in the development of lupus. Semin Immunol. 2011;23(2):113–121. doi: 10.1016/j.smim.2011.01.009.
   PubMed Web of Science ®Google Scholar
• Crow MK. Type I interferon in the pathogenesis of lupus. J Immunol. 2014;192(12):5459–5468. doi: 10.4049/jimmunol.1002795.
   PubMed Web of Science ®Google Scholar
• Crow MK, Olferiev M, Kirou KA. Targeting of type I interferon in systemic autoimmune diseases. Transl Res. 2015;165(2):296–305. doi: 10.1016/j.trsl.2014.10.005.
   PubMed Web of Science ®Google Scholar
• Crow MK. Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets. Ann Rheum Dis. 2023;82(8):999–1014. [cited 2024 Jun 5]. Available from: https://ard.bmj.com/content/early/2023/02/14/ard-2022-223741
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Kusuda M, Yamaguchi Y. Interferons and systemic lupus erythematosus: pathogenesis, clinical features, and treatments in interferon-driven disease. Mod Rheumatol. 2023;33(5):857–867. doi: 10.1093/mr/roac140.
   PubMed Web of Science ®Google Scholar
• Gallucci S, Meka S, Gamero AM. Abnormalities of the type I interferon signaling pathway in lupus autoimmunity. Cytokine. 2021;146:155633. doi: 10.1016/j.cyto.2021.155633.
   PubMed Web of Science ®Google Scholar
• Hooks JJ, Moutsopoulos HM, Geis SA, et al. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med. 1979;301(1):5–8. doi: 10.1056/NEJM197907053010102.
   PubMed Web of Science ®Google Scholar
• Ytterberg SR, Schnitzer TJ. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum. 1982;25(4):401–406. doi: 10.1002/art.1780250407.
   PubMed Web of Science ®Google Scholar
• Preble OT, Black RJ, Friedman RM, et al. Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. Science. 1982;216(4544):429–431. doi: 10.1126/science.6176024.
   PubMed Web of Science ®Google Scholar
• Kirou KA, Lee C, George S, et al. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 2005;52(5):1491–1503. doi: 10.1002/art.21031.
   PubMed Web of Science ®Google Scholar
• Hua J, Kirou K, Lee C, et al. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum. 2006;54(6):1906–1916. doi: 10.1002/art.21890.
   PubMed Web of Science ®Google Scholar
• Niewold TB, Adler JE, Glenn SB, et al. Age- and sex-related patterns of serum interferon-alpha activity in lupus families. Arthritis Rheum. 2008;58(7):2113–2119. doi: 10.1002/art.23619.
   PubMedGoogle Scholar
• Mathian A, Weinberg A, Gallegos M, et al. IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black × New Zealand White) F1 but not in BALB/c mice. J Immunol. 2005;174(5):2499–2506. doi: 10.4049/jimmunol.174.5.2499.
   PubMed Web of Science ®Google Scholar
• Santiago-Raber M-L, Baccala R, Haraldsson KM, et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med. 2003;197(6):777–788. doi: 10.1084/jem.20021996.
   PubMed Web of Science ®Google Scholar
• Braun D, Geraldes P, Demengeot J. Type I Interferon controls the onset and severity of autoimmune manifestations in lpr mice. J Autoimmun. 2003;20(1):15–25. doi: 10.1016/s0896-8411(02)00109-9.
   PubMed Web of Science ®Google Scholar
• Kälkner KM, Rönnblom L, Karlsson Parra AK, et al. Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon. Q J Med. 1998;91(6):393–399. doi: 10.1093/qjmed/91.6.393.
   Google Scholar
• Ehrenstein MR, McSweeney E, Swane M, et al. Appearance of anti-DNA antibodies in patients treated with interferon-alpha. Arthritis Rheum. 1993;36(2):279–280. doi: 10.1002/art.1780360224.
   PubMedGoogle Scholar
• Rönnblom LE, Alm GV, Oberg KE. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med. 1991;115(3):178–183. doi: 10.7326/0003-4819-115-3-178.
   PubMed Web of Science ®Google Scholar
• Khamashta M, Merrill JT, Werth VP, et al. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75(11):1909–1916. doi: 10.1136/annrheumdis-2015-208562.
   PubMed Web of Science ®Google Scholar
• Furie R, Khamashta M, Merrill JT, et al. Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 2017;69:376–386. doi: 10.1002/art.39962.
   PubMed Web of Science ®Google Scholar
• Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140(6):805–820. doi: 10.1016/j.cell.2010.01.022.
   PubMed Web of Science ®Google Scholar
• Chen Q, Sun L, Chen ZJ. Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing. Nat Immunol. 2016;17(10):1142–1149. doi: 10.1038/ni.3558.
   PubMed Web of Science ®Google Scholar
• Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4(7):499–511. doi: 10.1038/nri1391.
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature. 2008;455(7213):674–678. doi: 10.1038/nature07317.
   PubMed Web of Science ®Google Scholar
• Ablasser A, Goldeck M, Cavlar T, et al. cGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING. Nature. 2013;498(7454):380–384. doi: 10.1038/nature12306.
   PubMed Web of Science ®Google Scholar
• Zhang X, Shi H, Wu J, et al. Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING. Mol Cell. 2013;51(2):226–235. doi: 10.1016/j.molcel.2013.05.022.
   PubMed Web of Science ®Google Scholar
• Siegal FP, Kadowaki N, Shodell M, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science. 1999;284(5421):1835–1837. doi: 10.1126/science.284.5421.1835.
   PubMed Web of Science ®Google Scholar
• Cella M, Jarrossay D, Facchetti F, et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med. 1999;5(8):919–923. doi: 10.1038/11360.
   PubMed Web of Science ®Google Scholar
• Colonna M, Trinchieri G, Liu Y-J. Plasmacytoid dendritic cells in immunity. Nat Immunol. 2004;5(12):1219–1226. doi: 10.1038/ni1141.
   PubMed Web of Science ®Google Scholar
• Kwok S-K, Lee J-Y, Park S-H, et al. Dysfunctional interferon-alpha production by peripheral plasmacytoid dendritic cells upon Toll-like receptor-9 stimulation in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008;10(2):R29. doi: 10.1186/ar2382.
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11(5):373–384. doi: 10.1038/ni.1863.
   PubMed Web of Science ®Google Scholar
• Murayama G, Furusawa N, Chiba A, et al. Enhanced IFN-α production is associated with increased TLR7 retention in the lysosomes of palasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res Ther. 2017;19(1):234. doi: 10.1186/s13075-017-1441-7.
   PubMedGoogle Scholar
• Murayama G, Chiba A, Kuga T, et al. Inhibition of mTOR suppresses IFNα production and the STING pathway in monocytes from systemic lupus erythematosus patients. Rheumatology. 2020;59(10):2992–3002. doi: 10.1093/rheumatology/keaa060.
   PubMed Web of Science ®Google Scholar
• Gall A, Treuting P, Elkon KB, et al. Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease. Immunity. 2012;36(1):120–131. doi: 10.1016/j.immuni.2011.11.018.
   PubMed Web of Science ®Google Scholar
• Ahn J, Gutman D, Saijo S, et al. STING manifests self DNA-dependent inflammatory disease. Proc Natl Acad Sci USA. 2012;109(47):19386–19391. doi: 10.1073/pnas.1215006109.
   PubMed Web of Science ®Google Scholar
• Liu Y, Jesus AA, Marrero B, et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med. 2014;371(6):507–518. doi: 10.1056/NEJMoa1312625.
   PubMed Web of Science ®Google Scholar
• Baum R, Sharma S, Carpenter S, et al. Cutting edge: AIM2 and endosomal TLRs differentially regulate arthritis and autoantibody production in DNase II-deficient mice. J Immunol. 2015;194(3):873–877. doi: 10.4049/jimmunol.1402573.
   PubMed Web of Science ®Google Scholar
• Hirano R, Namazuda K, Hirata N. Double filtration plasmapheresis: review of current clinical applications. Ther Apher Dial. 2021;25(2):145–151. doi: 10.1111/1744-9987.13548.
   PubMed Web of Science ®Google Scholar
• Mineshima M. Double filtration plasmapheresis: determination of the optimal albumin concentration in the supplementation fluid. Transfus Apher Sci. 2017;56(5):654–656. doi: 10.1016/j.transci.2017.08.009.
   PubMed Web of Science ®Google Scholar
• Connelly-Smith L, Alquist CR, Aqui NA, et al. Guidelines on the use of therapeutic apheresis in clinical practice – evidence-based approach from the Writing Committee of the American Society for Apheresis: the ninth special issue. J Clin Apher. 2023;38(2):77–278. doi: 10.1002/jca.22043.
   PubMed Web of Science ®Google Scholar
• Jones JV, Cumming RH, Bucknall RC, et al. Plasmapheresis in the management of acute systemic lupus erythematosus? Lancet. 1976;1(7962):709–711. doi: 10.1016/s0140-6736(76)93088-9.
   PubMed Web of Science ®Google Scholar
• Yamaji K, Kim Y-J, Tsuda H, et al. Long-term clinical outcomes of synchronized therapy with plasmapheresis and intravenous cyclophosphamide pulse therapy in the treatment of steroid-resistant lupus nephritis. Ther Apher Dial. 2008;12(4):298–305. doi: 10.1111/j.1744-9987.2008.00591.x.
   PubMed Web of Science ®Google Scholar
• Li M, Wang Y, Qiu Q, et al. Therapeutic effect of double-filtration plasmapheresis combined with methylprednisolone to treat diffuse proliferative lupus nephritis: therapeutic effect of DFPP in diffuse proliferative LN. J Clin Apher. 2016;31(4):375–380. doi: 10.1002/jca.21408.
   PubMed Web of Science ®Google Scholar
• Al-Adhoubi NK, Bystrom J. Systemic lupus erythematosus and diffuse alveolar hemorrhage, etiology and novel treatment strategies. Lupus. 2020;29(4):355–363. doi: 10.1177/0961203320903798.
   PubMed Web of Science ®Google Scholar
• Furuichi K, Wada T. Apheresis for kidney disease. Contrib Nephrol. 2018;196:188–193. doi: 10.1159/000485721.
   PubMed Web of Science ®Google Scholar
• Kronbichler A, Brezina B, Quintana LF, et al. Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: a systematic review. Autoimmun Rev. 2016;15(1):38–49. doi: 10.1016/j.autrev.2015.08.010.
   PubMed Web of Science ®Google Scholar
• Jones JV, Cumming RH, Bacon PA, et al. Evidence for a therapeutic effect of plasmapheresis in patients with systemic lupus erythematosus. Q J Med. 1979;48(192):555–576.
   PubMedGoogle Scholar
• Krapf F, Manger B, Koch B, et al. The estimation of circulating immune complexes, C3d, and anti-ds-DNA-antibody serum levels in the monitoring of therapeutic plasmapheresis in a patient with systemic lupus erythematosus. A case report. Clin Exp Rheumatol. 1985;3:159–162.
   PubMed Web of Science ®Google Scholar
• Kato Y, Park J, Takamatsu H, et al. Apoptosis-derived membrane vesicles drive the cGAS–STING pathway and enhance type I IFN production in systemic lupus erythematosus. Ann Rheum Dis. 2018;77(10):1507–1515. doi: 10.1136/annrheumdis-2018-212988.
   PubMed Web of Science ®Google Scholar
• Tug S, Helmig S, Menke J, et al. Correlation between cell free DNA levels and medical evaluation of disease progression in systemic lupus erythematosus patients. Cell Immunol. 2014;292(1–2):32–39. doi: 10.1016/j.cellimm.2014.08.002.
   PubMed Web of Science ®Google Scholar
• Båve U, Magnusson M, Eloranta ML, et al. FcγRIIa is expressed on natural IFN-α-producing cells (plasmacytoid dendritic cells) and is required for the IFN-α production induced by apoptotic cells combined with lupus IgG 1. J Immunol. 2003;171(6):3296–3302. doi: 10.4049/jimmunol.171.6.3296.
   PubMed Web of Science ®Google Scholar
• Vallin H, Perers A, Alm GV, et al. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-α inducer in systemic lupus erythematosus. J Immunol. 1999;163(11):6306–6313. doi: 10.4049/jimmunol.163.11.6306.
   PubMed Web of Science ®Google Scholar
• Lood C, Blanco LP, Purmalek MM, et al. Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease. Nat Med. 2016;22(2):146–153. doi: 10.1038/nm.4027.
   PubMed Web of Science ®Google Scholar
• Emlen W, Ansari R, Burdick G. DNA-anti-DNA immune complexes. Antibody protection of a discrete DNA fragment from DNase digestion in vitro. J Clin Invest. 1984;74(1):185–190. doi: 10.1172/JCI111400.
   PubMed Web of Science ®Google Scholar
• Hartl J, Serpas L, Wang Y, et al. Autoantibody-mediated impairment of DNASE1L3 activity in sporadic systemic lupus erythematosus. J Exp Med. 2021;218(5):e20201138. doi: 10.1084/jem.20201138.
   PubMed Web of Science ®Google Scholar
• Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004;303(5663):1526–1529. doi: 10.1126/science.1093620.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Tago F, Yamakawa N, et al. A new therapeutic target for systemic lupus erythematosus: the current landscape for drug development of a toll-like receptor 7/8 antagonist through academia-industry-government collaboration. Immunol Med. 2024;47(1):24–29. doi: 10.1080/25785826.2023.2264023.
   PubMedGoogle Scholar
• Idborg H, Oke V. Cytokines as biomarkers in systemic lupus erythematosus: value for diagnosis and drug therapy. Int J Mol Sci. 2021;22(21):11327. doi: 10.3390/ijms222111327.
   PubMed Web of Science ®Google Scholar
• Caielli S, Wan Z, Pascual V. Systemic lupus erythematosus pathogenesis: interferon and beyond. Annu Rev Immunol. 2023;41(1):533–560. doi: 10.1146/annurev-immunol-101921-042422.
   PubMedGoogle Scholar
• Möckel T, Basta F, Weinmann-Menke J, et al. B cell activating factor (BAFF): structure, functions, autoimmunity and clinical implications in systemic lupus erythematosus (SLE). Autoimmun Rev. 2021;20(2):102736. doi: 10.1016/j.autrev.2020.102736.
   PubMed Web of Science ®Google Scholar
• Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721–731. doi: 10.1016/s0140-6736(10)61354-2.
   PubMed Web of Science ®Google Scholar
• Zhang F, Bae S-C, Bass D, et al. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis. 2018;77(3):355–363. doi: 10.1136/annrheumdis-2017-211631.
   PubMed Web of Science ®Google Scholar
• Oke V, Gunnarsson I, Dorschner J, et al. High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. Arthritis Res Ther. 2019;21(1):107. doi: 10.1186/s13075-019-1878-y.
   PubMedGoogle Scholar
• Gies V, Bekaddour N, Dieudonné Y, et al. Beyond anti-viral effects of chloroquine/hydroxychloroquine. Front Immunol. 2020;11:1409. doi: 10.3389/fimmu.2020.01409.
   PubMed Web of Science ®Google Scholar
• Fujio K. Functional genome analysis for immune cells provides clues for stratification of systemic lupus erythematosus. Biomolecules. 2023;13(4):591. doi: 10.3390/biom13040591.
   PubMed Web of Science ®Google Scholar
• Northcott M, Gearing LJ, Nim HT, et al. Glucocorticoid gene signatures in systemic lupus erythematosus and the effects of type I interferon: a cross-sectional and in-vitro study. Lancet Rheumatol. 2021;3(5):e357–e370. doi: 10.1016/S2665-9913(21)00006-0.
   PubMedGoogle Scholar
• Northcott M, Jones S, Koelmeyer R, et al. Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis. Lupus Sci Med. 2022;9(1):e000625. doi: 10.1136/lupus-2021-000625.
   PubMed Web of Science ®Google Scholar
• Casey KA, Guo X, Smith MA, et al. Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE. Lupus Sci Med. 2018;5(1):e000286. doi: 10.1136/lupus-2018-000286.
   PubMed Web of Science ®Google Scholar
• Dall’era MC, Cardarelli PM, Preston BT, et al. Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis. 2005;64(12):1692–1697. doi: 10.1136/ard.2004.033753.
   PubMed Web of Science ®Google Scholar
• Lin SL, Aw E, Zhang Y, et al. Interferon-alpha plays an important role in glial-mediated symptoms of neuropsychiatric systemic lupus erythematosus. J Immunol. 2023;210(1_Supplement):63.19–63.19. doi: 10.4049/jimmunol.210.Supp.63.19.
   Web of Science ®Google Scholar
• Stull D, O’Quinn S, Williams B, et al. Causal cascade of direct and indirect effects of anifrolumab on patient-reported outcomes: structural equation modelling of two phase 3 trials. Rheumatology. 2022;61(12):4731–4740. doi: 10.1093/rheumatology/keac138.
   PubMed Web of Science ®Google Scholar
• Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382(3):211–221. doi: 10.1056/nejmoa1912196.
   PubMed Web of Science ®Google Scholar
• Vital EM, Merrill JT, Morand EF, et al. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Ann Rheum Dis. 2022;81(7):951–961. doi: 10.1136/annrheumdis-2021-221425.
   PubMed Web of Science ®Google Scholar
• Bradford HF, Haljasmägi L, Menon M, et al. Inactive disease in patients with lupus is linked to autoantibodies to type I interferons that normalize blood IFNα and B cell subsets. Cell Rep Med. 2023;4(1):100894. doi: 10.1016/j.xcrm.2022.100894.
   PubMedGoogle Scholar
• Tanaka Y. Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice. RMD Open. 2023;9(3):e003270. doi: 10.1136/rmdopen-2023-003270.
   PubMed Web of Science ®Google Scholar